ManufacturingWith a $70 million expansion in Massachusetts, AbbVie plans...
Manufacturing

With a $70 million expansion in Massachusetts, AbbVie plans the next phase of its US investment adventure

Editotial Team
By Editotial Team

-

876
0

No content provided.

e8ca33a26f7037921e92de08cb2a519d8f9a37c9966383abf07edbf18b55cb25?s=150&d=mp&r=g
+ posts
Previous article
Rocket abandons its attempt to obtain FDA approval for bone marrow gene therapy
Next article
Aerska Launches with $21 Million to Develop RNAi Medicines for Neurological Diseases
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team

Latest news

Clinical

J&J Reports Positive Phase 2/3 Results for Imaavy in Warm Autoimmune Hemolytic Anemia

Johnson & Johnson has reported results from the pivotal phase 2/3 Energy study evaluating Imaavy in patients with warm...
Manufacturing

Edgewise Reports Phase 2 CIRRUS-HCM Results for EDG-7500 Ahead of Planned Phase 3 Development

Edgewise Therapeutics has reported top-line results from Part D of the Phase 2 CIRRUS-HCM trial evaluating EDG-7500 in patients...
Research & Development

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

The Advanced Research Projects Agency for Health (ARPA-H) has announced a new round of funding through its THRIVE program,...

Must read

Commercial

Commercial Excellence Summit Brings Together Leading Minds to Solve Critical Commercial Problems

This week is set to be a pivotal one...
Commercial

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you